Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PREP | P48147 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 3/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | NR1H2 | P55055 | 3/20 | 0.33 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.33 |
| ▸ | CTSK | P43235 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | PARP1 | P09874 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4942816 | 1.00 | PREP (0.36) | PREPHSD17B10ATMSMN1; SMN2NR1H2 | |
| SCHEMBL4939744 | 0.86 | PREP (0.35) | PREPHSD17B10ATMSMN1; SMN2CTSK | |
| SCHEMBL4942889 | 0.86 | PREP (0.35) | PREPHSD17B10ATMSMN1; SMN2CTSK | |
| SCHEMBL28976110 | 0.85 | NR1H2 (0.40) | PREPHSD17B10ATMSMN1; SMN2NR1H2 | |
| SCHEMBL3071568 | 0.85 | NR1H2 (0.40) | PREPHSD17B10ATMSMN1; SMN2NR1H2 | |
| SCHEMBL10215590 | 0.84 | PREP (0.37) | PREPHSD17B10ATMSMN1; SMN2NR1H2 | |
| SCHEMBL5049139 | 0.84 | SRC (0.37) | PREPATM | |
| SCHEMBL5049149 | 0.83 | ATM (0.37) | PREPHSD17B10ATMSMN1; SMN2NR1H2 | |
| SCHEMBL3082893 | 0.82 | PREP (0.36) | PREPHSD17B10ATMSMN1; SMN2NR1H2 | |
| SCHEMBL3081501 | 0.81 | CTSK (0.40) | PREPHSD17B10ATMSMN1; SMN2NR1H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080269131-A1 | Protein kinase B ; 4-(2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-{[(3S)-3-piperidinylmethyl]oxy}-1H-imidazo[4,5-c]pyridin-4-yl)-2-methyl-3-butyn-2-ol; 4-(2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-{[(2S)-2-morpholinylmethyl]oxy}-1H-imidazo[4,5-c]pyridin-4-yl)-2-methyl-3-butyn-2-ol; cancer and arthritis | SMITHKLINE BEECHAM CORPORATION | 2008-10-30 | — | — | US | disclosed |
| US-20080027211-A1 | Enantiopure Heterocyclic Compound Useful for the Preparation of Peptides Which Can Be Potentially Used as Medicaments | SOLVAY S.A. (BE) | 2008-01-31 | — | — | US | disclosed |
| CN-101035776-A | Enantiomerically pure heterocyclic compounds for the preparation of peptides potentially useful as medicaments | SOLVAY (BE) | 2007-09-12 | — | — | CN | disclosed |
| EP-1802595-A1 | ENANTIOPURE HETEROCYCLIC COMPOUND USEFUL FOR THE PREPARATION OF PEPTIDES WHICH CAN BE POTENTIALLY USED AS MEDICAMENTS | Solvay SA (BE) | 2007-07-04 | — | — | EP | disclosed |
| EP-1754703-A2 | N-Heterocyclic derivatives as nos inhibitors | Berlex, Inc. (US) | 2007-02-21 | — | — | EP | disclosed |
| EP-0968206-B8 | N-HETEROCYCLIC DERIVATIVES AS NOS INHIBITORS | BERLEX INC (US) | 2007-01-24 | — | — | EP | disclosed |
| EP-0968206-B1 | N-HETEROCYCLIC DERIVATIVES AS NOS INHIBITORS | BERLEX LAB (US) | 2006-11-15 | — | — | EP | disclosed |
| WO-2006037775-A1 | ENANTIOPURE HETEROCYCLIC COMPOUND USEFUL FOR THE PREPARATION OF PEPTIDES WHICH CAN BE POTENTIALLY USED AS MEDICAMENTS | Solvay (Société Anonyme) (BE) | 2006-04-13 | — | — | WO | disclosed |
| US-6887865-B2 | N-heterocyclic derivatives as NOS inhibitors | BERLEX LABORATORIES, INC. (US) | 2005-05-03 | — | — | US | disclosed |
| US-6864368-B2 | N-heterocyclic derivatives as NOS inhibitors | BERLAX LABORATORIES, INC. (US) | 2005-03-08 | — | — | US | disclosed |
| US-20030060452-A1 | N-heterocyclic derivatives as NOS inhibitors | BERLEX LABORATORIES, INC. (US) | 2003-03-27 | — | — | US | disclosed |
| US-20030027794-A1 | N-heterocyclic derivatives as NOS inhibitors | BERLEX LABORATORIES, INC. (US) | 2003-02-06 | — | — | US | disclosed |
| CN-1100777-C | N-heterocyclic derivatives as NOS inhibitor | BERLEX LAB (US) | 2003-02-05 | — | — | CN | disclosed |
| US-20030004137-A1 | N-heterocyclic derivatives as NOS inhibitors | BERLEX LABORATORIES, INC. (US) | 2003-01-02 | — | — | US | disclosed |
| US-20020183323-A1 | N-heterocyclic derivatives as NOS inhibitors | BERLEX LABORATORIES, INC. | 2002-12-05 | — | — | US | disclosed |
| US-20020165203-A1 | N-heterocyclic derivatives as NOS inhibitors | BERLEX LABORATORIES, INC. | 2002-11-07 | — | — | US | disclosed |
| US-6432947-B1 | NERVOUS SYSTEM DISORDERS; MUSCLE RELAXANTS; ANTIDIABETIC AGENTS | BERLEX LABORATORIES, INC. | 2002-08-13 | — | — | US | disclosed |
| CN-1252799-A | N-heterocyclic derivatives as NOS inhibitor | BERLEX LAB (US) | 2000-05-10 | — | — | CN | disclosed |
| EP-0968206-A1 | N-HETEROCYCLIC DERIVATIVES AS NOS INHIBITORS | BERLEX LABORATORIES, INC. (US) | 2000-01-05 | — | — | EP | disclosed |
| WO-1998037079-A1 | N-HETEROCYCLIC DERIVATIVES AS NOS INHIBITORS | BERLEX LABORATORIES, INC. (US) | 1998-08-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030060452-A1 | N-heterocyclic derivatives as NOS inhibitors | NOS1, NOS2, NOS3 | PREP 1092/4885HSD17B10 334/4885ATM 3477/4885 |
| US-20080027211-A1 | Enantiopure Heterocyclic Compound Useful for the Preparation of Peptides Which Can Be Potentially Used as Medicaments | NPR3, VIP, NPPA | PREP 186/4885HSD17B10 2245/4885ATM 4834/4885 |
| US-20030004137-A1 | N-heterocyclic derivatives as NOS inhibitors | NOS1, NOS2, NOS3 | PREP 1092/4885HSD17B10 334/4885ATM 3477/4885 |
| US-20080269131-A1 | Protein kinase B ; 4-(2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-{[(3S)-3-piperidinylmethyl]oxy}-1H-imidazo[4,5-c]pyridin-4-yl)-2-methyl-3-butyn-2-ol; 4-(2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-{[(2S)-2-morpholinylmethyl]oxy}-1H-imidazo[4,5-c]pyridin-4-yl)-2-methyl-3-butyn-2-ol; cancer and arthritis | MAP4K2, MAPKAPK2, PTK2B | PREP 3656/4885HSD17B10 4372/4885ATM 757/4885 |
| US-20020165203-A1 | N-heterocyclic derivatives as NOS inhibitors | NOS1, NOS2, NOS3 | PREP 1092/4885HSD17B10 334/4885ATM 3477/4885 |
| US-20030027794-A1 | N-heterocyclic derivatives as NOS inhibitors | NOS1, NOS2, NOS3 | PREP 1092/4885HSD17B10 334/4885ATM 3477/4885 |
| US-20020183323-A1 | N-heterocyclic derivatives as NOS inhibitors | NOS1, NOS2, NOS3 | PREP 1092/4885HSD17B10 334/4885ATM 3477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.